Form 8-K - Current report:
SEC Accession No. 0001641172-25-025752
Filing Date
2025-08-28
Accepted
2025-08-28 06:10:48
Documents
15
Period of Report
2025-08-22
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 45632
2 EX-16.1 ex16-1.htm EX-16.1 6104
3 GRAPHIC form8-k_001.jpg GRAPHIC 14451
  Complete submission text file 0001641172-25-025752.txt   304333

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cycc-20250822.xsd EX-101.SCH 3743
5 XBRL DEFINITION FILE cycc-20250822_def.xml EX-101.DEF 26581
6 XBRL LABEL FILE cycc-20250822_lab.xml EX-101.LAB 36613
7 XBRL PRESENTATION FILE cycc-20250822_pre.xml EX-101.PRE 25205
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5748
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)